Research & Development



  我在成都苦苦等候,卻等來了無情文書,為此,我不服,千里迢迢來到長安謀生,不為他,只想告訴他,離開他,我卓姬一樣可以活的輕松快活。   狗子正色道︰“雲氏真的沒有奴僕,家里有的只是大漢的子民,之所以沒有脫離奴籍,是因為很多人不願意脫離而已,任何人只要想,三天之內,他就會成為大漢百姓。”天无日天天射天天视   劉陵在長安生活的時候,並不喜歡長安這個地方,每日都是看厭倦了的景象,讓她心中對匈奴人的大草原充滿了渴望。天天啪天天舔天天透y   見桑弘羊已經見識了雲氏在皇帝心中的重要性,雲瑯就從書架上取下一本手抄的《春秋》放在桑弘羊的手里道︰“听說桑大夫一向喜愛《春秋》,今日恰逢其會,《春秋》的抄錄已經完成,總共六本,送先生一本。”   “你不喜歡左吳?”大色窝   亂糟糟的披在肩膀上,很有一種烈士暮年的樣子。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo